search button
Open Access

Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma

  • Authors:
    • Sven Lindner
    • Hagen S. Bachmann
    • Andrea Odersky
    • Simon Schaefers
    • Ludger Klein‑Hitpass
    • Barbara Hero
    • Matthias Fischer
    • Angelika Eggert
    • Alexander Schramm
    • Johannes H. Schulte

  • View Affiliations

  • Published online on: May 13, 2015     https://doi.org/10.3892/br.2015.463
  • Pages: 443-446

  • Copyright: © Lindner et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Maintenance of telomere length is a critical hallmark of malignant transformation. While silenced in somatic cells, telomerase reverse transcriptase (TERT), the catalytic subunit of telomerase, is frequently overexpressed in malignant cells thereby maintaining their telomere length. Specific point mutations in the TERT promoter region have recently been identified in melanoma and other tumor entities resulting in high TERT expression. Neuroblastoma is the most common extracranial tumor of childhood, arising from neural‑crest progenitor cells. TERT overexpression has been observed in the majority of neuroblastoma. Taking into consideration that TERT promoter mutations are frequently described in neural‑crest‑derived tumors such as melanoma, as well as a variety of other neuronal tumors, the present study analyzed the frequency of TERT promoter mutations in primary neuroblastoma and neuroblastoma cell lines. In 131 neuroblastoma primary tumors representing the whole spectrum of neuroblastoma, no TERT promoter mutations were detected. However, in 3 out of 19 neuroblastoma cell lines the previously described C228T TERT promoter mutation was present. In conclusion, the TERT promoter mutations are not a frequent mechanism of TERT overexpression in neuroblastoma.
View Figures
View References

Related Articles

Journal Cover

July-2015
Volume 3 Issue 4

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.3
  • Ranked
    (total number of cites)
  • CiteScore: 3.7
  • CiteScore Rank: Q2: #23/79 Pharmacology, Toxicology and Pharmaceutics
  • Source Normalized Impact per Paper (SNIP): 0.742
  • SCImago Journal Rank (SJR): 0.488
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Lindner S, Bachmann HS, Odersky A, Schaefers S, Klein‑Hitpass L, Hero B, Fischer M, Eggert A, Schramm A, Schulte JH, Schulte JH, et al: Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma. Biomed Rep 3: 443-446, 2015
APA
Lindner, S., Bachmann, H.S., Odersky, A., Schaefers, S., Klein‑Hitpass, L., Hero, B. ... Schulte, J.H. (2015). Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma. Biomedical Reports, 3, 443-446. https://doi.org/10.3892/br.2015.463
MLA
Lindner, S., Bachmann, H. S., Odersky, A., Schaefers, S., Klein‑Hitpass, L., Hero, B., Fischer, M., Eggert, A., Schramm, A., Schulte, J. H."Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma". Biomedical Reports 3.4 (2015): 443-446.
Chicago
Lindner, S., Bachmann, H. S., Odersky, A., Schaefers, S., Klein‑Hitpass, L., Hero, B., Fischer, M., Eggert, A., Schramm, A., Schulte, J. H."Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma". Biomedical Reports 3, no. 4 (2015): 443-446. https://doi.org/10.3892/br.2015.463